Dysautonomia (Autonomic Dysfunction) Global Market Report 2025

The dysautonomia (autonomic dysfunction) market size has grown rapidly in recent years. It will grow from $2.62 billion in 2024 to $2.92 billion in 2025 at a compound annual growth rate (CAGR) of 11.8%. The growth during the historic period can be attributed to factors such as the rising prevalence of autonomic disorders, greater awareness of dysautonomia, increased healthcare spending, expanding research into neurodegenerative diseases, and growing government support for rare diseases.

The dysautonomia (autonomic dysfunction) market size is expected to see rapid growth in the next few years. It will grow to $4.53 billion in 2029 at a compound annual growth rate (CAGR) of 11.5%. The growth during the forecast period can be attributed to factors such as the increasing adoption of personalized medicine, a rise in clinical trials for novel treatments, growing government funding for rare disease research, the expansion of telemedicine and remote monitoring solutions, and greater availability of orphan drugs. Key trends expected in this period include the integration of artificial intelligence in diagnostics, the development of targeted therapies, the use of wearable devices for autonomic monitoring, advancements in gene therapies, and innovation in patient-centric treatment approaches.

The rising prevalence of chronic diseases is expected to drive the growth of the dysautonomia (autonomic dysfunction) market. Chronic diseases are long-lasting conditions that persist for more than three months, and their increase is linked to factors such as the growing occurrence of multimorbidity, where individuals are diagnosed with multiple chronic disorders simultaneously. Dysautonomia plays a significant role in these conditions by disrupting the body's ability to regulate critical functions such as heart rate, blood pressure, and digestion, often worsening symptoms and complicating treatment. For example, in October 2023, the National Health Service in the UK reported that the prevalence of Type 1 diabetes in England rose from 261,710 cases in 2020-21 to 270,935 cases in 2021-22, marking a 3.5% increase year-over-year. As chronic diseases become more common, the dysautonomia market is expected to expand.

The growing number of autoimmune and neurological disorders is also expected to drive market growth. Autoimmune and neurological disorders occur when the immune system mistakenly attacks the nervous system, causing inflammation, damage, and dysfunction in the brain, spinal cord, or peripheral nerves. This increase is attributed to factors such as genetic predisposition, environmental triggers, lifestyle changes, infections, and better diagnostic techniques. Dysautonomia is often a key indicator of these disorders, as its presence in conditions such as Sjӧgren’s syndrome, multiple sclerosis, Parkinson’s disease, and multiple system atrophy (MSA) helps doctors identify, monitor, and manage disease progression and create more targeted treatments. For instance, in July 2023, Public Health Scotland reported that the number of newly diagnosed multiple sclerosis patients rose by 87.2% in 2022, with 491 new cases reported, bringing the total to 6,359. As autoimmune and neurological disorders increase, the dysautonomia market is expected to continue growing.

Companies are focusing on developing new treatments using recombinant adeno-associated viruses (rAAV) to deliver therapeutic genes to target cells more effectively. rAAV is a modified virus used in gene therapy to introduce genetic material into cells without causing disease. For example, in January 2025, Tikun Therapeutics Inc., a U.S.-based biotechnology company, received FDA approval for Orphan Drug and Rare Pediatric Disease Designations for its gene therapy treatments rAAV2-U1a-hELP1, designed for optic neuropathy in familial dysautonomia, and BPN-36964, a small molecule splicing modulator for systemic FD treatment. These therapies aim to address the genetic causes of familial dysautonomia, offering long-term benefits beyond symptomatic treatment.

Major players in the dysautonomia (autonomic dysfunction) market are Teva Pharmaceutical Industries Ltd., H. Lundbeck A/S, Aurobindo Pharma Limited, Hikma Pharmaceuticals PLC, Cadila Healthcare Limited (Zydus Cadila), Lupin Limited, Nemours Children's Health Delaware, Alnylam Pharmaceuticals Inc., Biohaven Pharmaceuticals Holding Company Ltd., Aurora Health Care Inc., Camber Pharmaceuticals Inc., Theravance Biopharma Inc., Tocris Bioscience a subsidiary of Bio-Techne Corporation, Celltex Therapeutics Corporation, DyAnsys Inc., Axplora Inc., MODAG GmbH, Inhibikase Therapeutics Inc., Mylan Pharmaceuticals Private Limited, Chelsea Therapeutics International Ltd.

North America was the largest region in the dysautonomia (autonomic dysfunction) market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in dysautonomia (autonomic dysfunction) report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

The countries covered in the dysautonomia (autonomic dysfunction) market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Dysautonomia, or autonomic dysfunction, refers to a condition in which the autonomic nervous system (ANS) malfunctions, affecting involuntary bodily functions such as heart rate, blood pressure, digestion, and temperature regulation. It can be caused by various factors such as genetic predispositions, injuries, or underlying health conditions, leading to symptoms such as dizziness, fainting, and irregular heartbeats.

The primary types of dysautonomia (autonomic dysfunction) include neurogenic orthostatic hypotension (NOH), postural orthostatic tachycardia syndrome (POTS), multiple system atrophy (MSA), pure autonomic failure (PAF), and other forms. Neurogenic orthostatic hypotension occurs due to autonomic nervous system dysfunction, causing a significant drop in blood pressure when standing, which results in dizziness, lightheadedness, and fainting. Diagnosing dysautonomia involves tests such as cardiovagal and vasomotor function assessments, the thermoregulatory sweat test (TST), sympathetic skin response (SSR), and the quantitative sudomotor axon reflex test, among others. Treatment options include physical therapy, exercise therapy, counseling, and other therapeutic interventions. Medications and treatments are distributed through hospital pharmacies, online pharmacies, and retail pharmacies, with key end users being hospitals, clinics, diagnostic centers, and research institutes.

The dysautonomia (autonomic dysfunction) market research report is one of a series of new reports that provides dysautonomia (autonomic dysfunction) market statistics, including the dysautonomia (autonomic dysfunction) industry global market size, regional shares, competitors with the dysautonomia (autonomic dysfunction) market share, detailed dysautonomia (autonomic dysfunction) market segments, market trends, and opportunities, and any further data you may need to thrive in the dysautonomia (autonomic dysfunction) industry. This dysautonomia (autonomic dysfunction) market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.

The dysautonomia (autonomic dysfunction) market consists of revenues earned by entities by providing services such as pharmaceutical treatment, radiation therapy, diagnostic services, and surgical interventions. The market value includes the value of related goods sold by the service provider or included within the service offering. The dysautonomia (autonomic dysfunction) market also includes sales of diagnostic tools, intravenous therapies, neurostimulatory devices, compression garments, and electrolyte supplements. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 3-5 business days.